A randomized phase 2 study of sapanisertib in combination with paclitaxel versus paclitaxel alone in women with advanced, recurrent, or persistent endometrial cancer

This phase 2 study investigated sapanisertib (selective dual inhibitor of mTORC1/2) alone, or in combination with paclitaxel or TAK-117 (a selective small molecule inhibitor of PI3K), versus paclitaxel alone in advanced, recurrent, or persistent endometrial cancer. Patients with histologic diagnosis...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Gynecologic oncology 2023-11, Vol.178, p.110-118
Hauptverfasser:	Han, Sileny N., Oza, Amit, Colombo, Nicoletta, Oaknin, Ana, Raspagliesi, Francesco, Wenham, Robert M., Braicu, Elena Ioana, Jewell, Andrea, Makker, Vicky, Krell, Jonathan, Alía, Eva María Guerra, Baurain, Jean-François, Su, Zhenqiang, Neuwirth, Rachel, Vincent, Sylvie, Sedarati, Farhad, Faller, Douglas V., Scambia, Giovanni
Format:	Artikel
Sprache:	eng
Schlagworte:	Advanced Antineoplastic Combined Chemotherapy Protocols - adverse effects Endometrial cancer Endometrial Neoplasms - drug therapy Endometrial Neoplasms - etiology Female Humans Mammalian target of rapamycin complexes 1 and 2 inhibitor Metastatic Paclitaxel Paclitaxel - adverse effects Progression-Free Survival Recurrent Sapanisertib Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!